Asensio-Sanchez VM. Re: Freedman et al: Low- and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes (Ophthalmology. 2022;129:1120-1128). Ophthalmology 2023 Jan 20:S0161-6420(22)01010.
PMID: 36702728